Patents by Inventor Gennaro Ciliberto

Gennaro Ciliberto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210147945
    Abstract: miRNAs for in vitro diagnosis of resistance of tumors to BRAF/MEK pathway (also named as MAPK 5 pathway) inhibiting drugs and for treatment of tumors which are treated with said drugs, such as melanoma, by stimulating or inhibiting the expression of down-regulated or up-regulated miRNAs, respectively.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 20, 2021
    Inventors: Gennaro CILIBERTO, Paolo Antonio ASCIERTO, Luigi FATTORE, Gerardo BOTTI, Rita MANCINI
  • Patent number: 10836792
    Abstract: The present invention discloses retro-inverso peptides and pharmaceutical composition containing them. The peptides of the invention prevent key events occurring during the metastatic process, i.e. invasion of the extracellular matrix, formation of a capillary network, and the entry into bloodstream. They are therefore useful in the treatment of diseases and conditions that are sustained by an increase of cell motility, cell invasion, and/or angiogenesis, such as tumors and chronic inflammation.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: November 17, 2020
    Assignee: ISTITUTO NAZIONALE TUMORI IRCCS “FONDAZIONE G. PASCALE”
    Inventors: Maria Vincenza Carriero, Gennaro Ciliberto, Katia Bifulco, Antonello Pessi
  • Patent number: 10745459
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 18, 2020
    Assignee: TAKIS S.R.L.
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • Publication number: 20190135863
    Abstract: The present invention discloses retro-inverso peptides and pharmaceutical composition containing them. The peptides of the invention prevent key events occurring during the metastatic process, i.e. invasion of the extracellular matrix, formation of a capillary network, and the entry into bloodstream. They are therefore useful in the treatment of diseases and conditions that are sustained by an increase of cell motility, cell invasion, and/or angiogenesis, such as tumors and chronic inflammation.
    Type: Application
    Filed: April 6, 2017
    Publication date: May 9, 2019
    Applicant: ISTITUTO NAZIONALE TUMORI IRCCS "FONDAZIONE G. PASCALE"
    Inventors: Maria Vincenza Carriero, Gennaro Ciliberto, Katia Bifulco, Antonello Pessi
  • Publication number: 20170342123
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Application
    Filed: June 1, 2017
    Publication date: November 30, 2017
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • Patent number: 9688738
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: June 27, 2017
    Assignee: TAKIS S.R.L.
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • Publication number: 20140017259
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Application
    Filed: November 2, 2011
    Publication date: January 16, 2014
    Applicant: TAKIS S.R.L.
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • Patent number: 8492522
    Abstract: Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 23, 2013
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Luigi Aurisicchio, Daniela Peruzzi, Nicola La Monica, Gennaro Ciliberto, Domenico Lazzaro, Federica Mori
  • Publication number: 20120177679
    Abstract: Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.
    Type: Application
    Filed: December 21, 2011
    Publication date: July 12, 2012
    Applicant: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA
    Inventors: LUIGI AURISICCHIO, DANIELA PERUZZI, NICOLA LA MONICA, GENNARO CILIBERTO, DOMENICO LAZZARO, FEDERICA MORI
  • Patent number: 8188244
    Abstract: Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of an immunoenhancing element. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type CEA. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding CEA fusion proteins and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
    Type: Grant
    Filed: February 3, 2005
    Date of Patent: May 29, 2012
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Nicola La Monica, Andrea Facciabene, Luigi Aurisicchio, Gennaro Ciliberto
  • Patent number: 8106176
    Abstract: Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: January 31, 2012
    Assignee: Instituto di Richerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Luigi Aurisicchio, Daniela Peruzzi, Nicola La Monica, Gennaro Ciliberto, Domenico Lazzaro, Federica Mori
  • Patent number: 8017387
    Abstract: Polynucleotides encoding telomerase reverse transcriptase (TERT) fusion proteins are provided, the TERT fusion proteins comprising a TERT protein, or functional variant thereof, fused to a substantial portion of the B subunit of heat labile enterotoxin (LTB). TERT variants useful in TERT-LTB fusion proteins of the invention comprise mutations that function to eliminate telomerase catalytic activity. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type TERT. TERT expression is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the TERT tumor-associated antigen, wherein aberrant TERT expression is associated with a carcinoma or its development.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: September 13, 2011
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Elisa Scarselli, Carmela Mennuni, Nicola La Monica, Gennaro Ciliberto
  • Publication number: 20110182926
    Abstract: The present invention provides minigenes suitable as a prophylactic or therapeutic vaccine against conditions such as cancer, infectious diseases or autoimmune diseases, and pharmaceutical compositions comprising the minigene. The minigenes of the present invention comprise (a) a human tissue plasminogen signal peptide; (b) at least one T-cell epitope; and (c) an E. coli heat labile enterotoxin B subunit; wherein the at least one T-cell epitope is linked to the rest of the minigene, and to any other epitopes, by furin sensitive linkers. In some embodiments of the invention, the minigene comprises T-cell epitopes from one or more of CEA, her-2/neu and hTERT. Also provided herein are immunogenic peptide epitopes of CEA, her-2/neu and hTERT, as well as immunogenic peptide analogs, and pharmaceutical compositions and vaccines comprising one or more of said peptides and analogs for prophylaxis and/or treatment of cancer or other disorder.
    Type: Application
    Filed: August 7, 2009
    Publication date: July 28, 2011
    Inventors: Nicola La Monica, Elisa Scarselli, Gennaro Ciliberto, Luigi Aurisicchio, Arthur Fridman, Ansuman Bagchi
  • Publication number: 20090155298
    Abstract: Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid en->coding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.
    Type: Application
    Filed: October 3, 2006
    Publication date: June 18, 2009
    Inventors: Luigi Aurisicchio, Daniela Peruzzi, Nicola La Monica, Gennaro Ciliberto, Domenico Lazzaro, Federica Mori
  • Publication number: 20080311137
    Abstract: Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of an immunoenhancing element. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type CEA. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding CEA fusion proteins and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
    Type: Application
    Filed: February 3, 2005
    Publication date: December 18, 2008
    Inventors: Nicola La Monica, Andrea Facciabene, Luigi Aurisicchio, Gennaro Ciliberto
  • Publication number: 20080090778
    Abstract: Polynucleotides encoding telomerase reverse transcriptase (TERT) fusion proteins are provided, the TERT fusion proteins comprising a TERT protein, or functional variant thereof, fused to a substantial portion of the B subunit of heat labile enterotoxin (LTB). TERT variants useful in TERT-LTB fusion proteins of the invention comprise mutations that function to eliminate telomerase catalytic activity. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type TERT. TERT expression is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the TERT tumor-associated antigen, wherein aberrant TERT expression is associated with a carcinoma or its development.
    Type: Application
    Filed: October 11, 2007
    Publication date: April 17, 2008
    Inventors: Elisa Scarselli, Carmela Mennuni, Nicola La Monica, Gennaro Ciliberto
  • Patent number: 7282365
    Abstract: Polynucleotides encoding rhesus monkey HER2/neu have been isolated, cloned and sequenced. The gene encoding the HER2/neu is commonly associated with the development of epithelial-derived human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the HER2/neu tumor-associated antigen, wherein aberrant HER2/neu expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector constructs carrying rhHER2/neu and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: October 16, 2007
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Paolo Monaci, Maurizio Nuzzo, Nicola La Monica, Gennaro Ciliberto, Armin Lahm
  • Publication number: 20070087346
    Abstract: The present invention relates to an orthogonal gene switch for regulating the expression of a desired gene. The gene switch comprises a chimeric transcription factor that does not respond to endogenous ligands, and a ligand that is capable of activating the chimeric transcription factor but not endogenous transcription factors. The present invention also relates to the method of constructing the orthogonal gene switch.
    Type: Application
    Filed: October 15, 2004
    Publication date: April 19, 2007
    Inventors: Gennaro Ciliberto, Raffaele De Francesco, Fattori Daniela, Paolo Gallinari, Olaf Kinzel, Uwe Koch, Ester Muraglia, Carlo Toniatti
  • Publication number: 20060286114
    Abstract: Synthetic polynucleotides encoding rhesus monkey carcinoembryonic antigen (CEA) are provided, the synthetic polynucleotides being condon-optimized for expression in a human cellular environment. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenovial vector and plasmid constructs carrying codon-optimed rhesus monkey CEA and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
    Type: Application
    Filed: August 17, 2004
    Publication date: December 21, 2006
    Inventors: Luigi Aurisicchio, Nicola La Monica, Patrizia Giannetti, Gennaro Ciliberto
  • Publication number: 20060239969
    Abstract: Polynucleotides encoding rhesus monkey HER2/neu have been isolated, cloned and sequenced. The gene encoding the HER2/neu is commonly associated with the development of epithelial-derived human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the HER2/neu tumor-associated antigen, wherein aberrant HER2/neu expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector constructs carrying rhHER2/neu and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
    Type: Application
    Filed: December 29, 2003
    Publication date: October 26, 2006
    Inventors: Paolo Monaci, Maurizio Nuzzo, Nicola La Monica, Gennaro Ciliberto, Armin Lahm